👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

HSBC lifts TSMC target on strong Q3 sales, maintains Buy

EditorTanya Mishra
Published 10/11/2024, 11:04 AM
TSM
-

HSBC updated its financial outlook for Taiwan Semiconductor Manufacturing Co. Ltd. (2330:TT) (NYSE: TSM), raising the price target to NT$1,535.00 from the previous NT$1,410.00. The firm has kept its Buy rating on the stock. This adjustment comes after TSMC reported robust sales figures for the third quarter of 2024, which surpassed their own revenue projections as well as market estimates.

TSMC's third-quarter revenue reached TWD760 billion, marking a 13% increase from the previous quarter and exceeding the company's forecasted range of TWD728-754 billion. The reported revenue was also consistent with the projections made by HSBC and other analysts, which stood at TWD743 billion and TWD749 billion, respectively. The success is attributed to the strong performance of TSMC's advanced nodes, particularly as the 3nm technology continues to gain traction.

The semiconductor giant is expected to achieve a gross margin of 55.5% for the third quarter, according to the analyst. This figure not only surpasses the consensus estimate of 54.7% but also sits at the upper end of TSMC's own guidance range of 53.5% to 55.5%. The precise details regarding the company's financial performance will be further clarified during TSMC's third-quarter earnings call, which is scheduled for October 17, 2024.

Investors and industry observers look forward to the earnings call for a comprehensive analysis of the company's financial health and future outlook.

Taiwan Semiconductor Manufacturing Company (TSMC) displayed robust performance in the second quarter of 2024, with a 13.6% sequential revenue increase and a gross margin rise to 53.2%. The High-Performance Computing (HPC) segment accounted for 52% of total revenue. Furthermore, TSMC raised its full-year revenue guidance to a growth rate slightly above the mid-20s percent in USD terms. The company's capital expenditure for 2024 is projected to be between USD 30 billion and USD 32 billion, primarily allocated to advanced process technologies.

JPMorgan maintained its Overweight rating on TSMC, citing expectations for a robust third-quarter earnings report. The firm anticipates that TSMC's revenue will slightly exceed the company's forecast, with projected revenues of US $23.3 billion. BofA Securities reiterated a Buy rating, highlighting the upcoming delivery of a high-numerical aperture extreme ultraviolet (EUV) lithography tool to TSMC from ASML (AS:ASML), which is expected to enhance the company's capabilities in developing advanced semiconductor processes.

Bernstein SocGen Group updated its outlook on TSMC, increasing the price target to $220 and retaining an Outperform rating on the stock. The firm suggests TSMC is well-positioned to perform better than its peers should a recession occur, due to its advanced technologies and market share gains.

InvestingPro Insights

TSMC's robust financial performance, as highlighted in the article, is further supported by real-time data from InvestingPro. The company's market capitalization stands at an impressive $822.11 billion, reflecting its dominant position in the semiconductor industry. TSMC's revenue growth remains strong, with a 40.07% increase in the most recent quarter, aligning with the article's mention of the company surpassing its own revenue projections.

InvestingPro Tips emphasize TSMC's financial strength. One tip notes that the company has demonstrated consistent earnings growth, which is evident in its reported revenue increase and expected gross margin improvement. Another tip highlights TSMC's strong cash flow generation, which supports its ability to invest in advanced technologies like the 3nm node mentioned in the article.

These insights complement the article's focus on TSMC's performance and future outlook. InvestingPro offers 13 additional tips for TSMC, providing investors with a more comprehensive analysis of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.